MK-0616   Click here for help

GtoPdb Ligand ID: 12689

Synonyms: MK0616
Compound class: Synthetic organic
Comment: MK-0616 is an oral, macrocyclic peptide inhibitor of the dyslipidemia drug target proprotein convertase subtilisin/kexin type 9 (PCSK9) [3]. Functionally, MK-0616 binds to PCSK9 and prevents its interaction with, and degradation of, the low-density lipoprotein receptor, which results in reduced plasma LDL-C concentration.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 29
Hydrogen bond donors 9
Rotatable bonds 43
Topological polar surface area 439.37
Molecular weight 1615.96
XLogP 1.47
No. Lipinski's rules broken 4
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC1=CC(=CC(=C1)C)N2C=C(CN3C=C(C[C@H]4C(=O)N5CC[C@@H]([C@H]5C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC6=CC=C(C=C6)OC)C(=O)N7CCC[C@@]7(C)C(=O)NCCS)OC/C=C/CC8=CC=CC(=C8)C[C@@H](C(=O)N4)NC(=O)[C@@H](C)NC(=O)[C@H](CNC(=O)CCOCCOCC[N+](C)(C)C)NC(=O)CCS)C9=C3C=CC(=C9)F)N=N2
Isomeric SMILES CC1=CC(=CC(=C1)N2C=C(N=N2)CN3C=C(C4=C3C=CC(=C4)F)C[C@H]5C(=O)N6CC[C@@H]([C@H]6C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC7=CC=C(C=C7)OC)C(=O)N8CCC[C@@]8(C)C(=O)NCCS)OC/C=C/CC9=CC(=CC=C9)C[C@@H](C(=O)N5)NC(=O)[C@@H](C)NC(=O)[C@H](CNC(=O)CCOCCOCC[N+](C)(C)C)NC(=O)CCS)C
InChI InChI=1S/C81H108FN15O15S2/c1-50-38-51(2)40-60(39-50)96-49-59(91-92-96)48-93-47-57(62-45-58(82)19-22-67(62)93)44-65-78(106)94-29-23-68(72(94)77(105)90-71(53(4)98)76(104)89-64(42-55-17-20-61(109-9)21-18-55)79(107)95-28-13-26-81(95,5)80(108)83-27-37-114)112-31-11-10-14-54-15-12-16-56(41-54)43-63(74(102)88-65)87-73(101)52(3)85-75(103)66(86-70(100)25-36-113)46-84-69(99)24-32-110-34-35-111-33-30-97(6,7)8/h10-12,15-22,38-41,45,47,49,52-53,63-66,68,71-72,98H,13-14,23-37,42-44,46,48H2,1-9H3,(H9-,83,84,85,86,87,88,89,90,99,100,101,102,103,104,105,108,113,114)/p+1/b11-10+/t52-,53-,63+,64+,65+,66+,68+,71+,72+,81+/m1/s1
InChI Key WQYKXIAUKXSSIN-ZPWCAMBLSA-O
References
1. A-González N, Castrillo A. (2011)
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
Biochim Biophys Acta, 1812 (8): 982-94. [PMID:21193033]
2. Ballantyne CM, Banka P, Mendez G, Garcia R, Rosenstock J, Rodgers A, Mendizabal G, Mitchel Y, Catapano AL. (2023)
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616.
J Am Coll Cardiol, 81 (16): 1553-1564. [PMID:36889610]
3. Johns DG, Campeau LC, Banka P, Bautmans A, Bueters T, Bianchi E, Branca D, Bulger PG, Crevecoeur I, Ding FX et al.. (2023)
Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor.
Circulation, 148 (2): 144-158. [PMID:37125593]